Molbio Diagnostics Aims for ₹200 Crore with IPO Amid Global Expansion

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is preparing to launch an initial public offering (IPO) to raise ₹200 crore. The funds will be directed towards capital expenditures as the company looks to fortify its global presence. Additionally, an offer for sale is set to generate ₹740 crore, reducing the promoter group's stake from 46.6% to 43%.

Revenue Growth and Market Presence

Founded in 2000, Molbio Diagnostics has established itself with six manufacturing facilities across India, serving over 90 countries. The company's success largely hinges on its tuberculosis diagnostic test kits, which contribute significantly to its revenue. In fact, 74% of Molbio's revenue comes from the sale of test kits, with 70% of this segment attributed to TB diagnostics.

The company's financial performance has been robust, with a 31.5% annual increase in revenue to ₹1,445.7 crore between FY24 and FY26. Net profit also saw a substantial rise, growing 40.2% annually to ₹164.1 crore. The operating profit before interest, tax, depreciation, and amortization (EBITDA) increased by 33.2% to ₹328.2 crore, with the EBITDA margin improving to 22.6% in FY26 from 22% in FY24.

Strategic Innovations and Client Concentration

Molbio's innovation is exemplified by its 'Truenat' platform, a portable diagnostic system designed for resource-limited settings, providing accurate results within an hour. The company offers solutions for over 30 diseases through 43 diagnostic assays. Additionally, it expands its offerings with radiology, digital pathology, and breast health screening solutions via subsidiaries and collaborations.

Despite its strong market position, Molbio faces challenges with customer concentration, as its top clients account for more than half of its revenue. Government and international aid agencies contribute over 80% of the company's revenue, highlighting a reliance on a limited client base.

Valuation and Competitive Landscape

Post-IPO, Molbio Diagnostics is expected to command a price-earnings (P/E) multiple of up to 57, which positions it within the range of other Indian healthcare diagnostics and medical device companies like Poly Medicure and Dr. Lal PathLabs, whose P/E ratios vary between 54 and 81. Although Molbio lacks a directly comparable listed peer in India, its valuation reflects its strong earnings growth and market potential.

For investors willing to embrace high-risk opportunities, Molbio's IPO presents a potential avenue for long-term growth, driven by its strategic innovations and expanding global footprint.